Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen

Executive Summary

Product tampering resulted in contents from eight vials of Epogen (epoetin alfa) and Neupogen (filgrastim) 300 mcg being extracted and the vials refilled with a replacement solution, the company said in a Feb. 13 "Dear Healthcare Provider" letter. "Although the replacement solution has thus far been shown to be non-toxic, the sterility of these vials was compromised," therefore posing a safety risk, especially for immune compromised patients, the letter states
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS037345

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel